Founded in 2022 and headquartered in Emeryville, CA, Profluent is backed by leading investors including Altimeter Capital, Bezos Expeditions, Spark Capital, Insight Partners, Air Street Capital, AIX Ventures, and Convergent Ventures and has raised over $150M to date. The ideal candidate will have a strong track record of engineering molecular systems for mammalian cells, with expertise in gene editing, nucleic acid biochemistry, protein-nucleic acid engineering, or molecular virology.